Estradiol Acetate

Summary

Estradiol Acetate (CHEMBL1200430) is an approved small molecule; indicated across 2 conditions.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• Indications: 2 conditions
• Clinical trials: 1
• Chemistry: 314.4 Da · C20H26O3

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL1200430
Name	Estradiol Acetate
Type	Small molecule
Max phase	4
FDA approved	yes
PubChem CID	9818306
Molecular formula	C20H26O3
Molecular weight	314.4
InChIKey	FHXBMXJMKMWVRG-SLHNCBLASA-N

SMILES: CC(=O)OC1=CC2=C(C=C1)[C@H]3CC[C@]4([C@H]([C@@H]3CC2)CC[C@@H]4O)C

IUPAC name: [(8R,9S,13S,14S,17S)-17-hydroxy-13-methyl-6,7,8,9,11,12,14,15,16,17-decahydrocyclopenta[a]phenanthren-3-yl] acetate

Also known as: E3A, Estradiol acetate, Femring, Femtrace, SID11533023, ESTRADIOL ACETATE, SID56422403, SID144204912, SID170465258, estradiol acetate

Patent coverage: 344 distinct patent families (1,114 SureChEMBL compound mentions), from 2 matched compound structure(s). One matched structure accounts for 1,112 (100%) of the total. Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Broader ChEMBL bioactivity targets: 14 (assay-derived). Sample: Nuclear receptor ROR-gamma, Survival motor neuron protein, Prelamin-A/C, Androgen receptor, Estrogen receptor, Thromboxane A2 receptor, Progesterone receptor, Muscarinic acetylcholine receptor M1, Alpha-1A adrenergic receptor, Mu-type opioid receptor, Sodium-dependent dopamine transporter, Adenosine receptor A3, Cruzipain, Serine-protein kinase ATM.

Bioactivity

ChEMBL activities: 7 potent at pChembl ≥ 5 of 14 total. Top 100 by potency (10 = 0.1 nM, 6 = 1 µM):

Target	pChembl	Type	Value	Unit	Activity ID
ESR1	7.65	AC50	22.4	nM	CHEMBL_ACT_25138988
AR	7.53	AC50	29.6	nM	CHEMBL_ACT_25203488
PGR	6.68	AC50	208.6	nM	CHEMBL_ACT_25204421
SMN1	5.9	Potency	1259	nM	CHEMBL_ACT_3878543
CHRM1	5.14	AC50	7242	nM	CHEMBL_ACT_25210323
SLC6A3	5.09	AC50	8092	nM	CHEMBL_ACT_25125089
OPRM1	5.04	AC50	9042	nM	CHEMBL_ACT_25158305

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

2 indication records carry no mapped disease name (EFO/MeSH-only); none shown.

Clinical trials

Total trials: 1.

Phase distribution

Phase	Trials
PHASE3	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT01070979	PHASE3	COMPLETED	Hormone Replacement Therapy for Use in Postmenopausal Women for Relief of Hot Flushes and Urogenital Symptoms.

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).